FDA Tunes Up Mammogram Rules: Keep Scans Sharp and Safe
Published Date: 3/13/2026
Notice
Summary
The FDA is asking for public feedback on renewing rules that keep mammogram centers safe and reliable. These rules affect mammography facilities, making sure their equipment, staff, and practices meet high standards. Comments are due by April 13, 2026, and this process helps protect patients without adding extra costs.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 1 costs, 1 mixed.
Continued Mammography Certification Rules
The rule keeps in place Federal requirements under 21 CFR part 900 that mammography facilities must be accredited by an FDA-approved accreditation body and then certified by FDA or an FDA-approved State certification agency. Facilities must meet equipment, personnel, quality assurance, and quality control standards and must prominently display their certificate to assure safe, reliable mammography nationwide.
Large Compliance Burden on Facilities
The information-collection renewal documents the compliance burden on mammography facilities, accreditation bodies, and State certifiers with specific estimated hours: annual reporting burden is 12,038 hours (Table 1), recordkeeping burden is 244,774 hours (Table 2), and third-party disclosure burden is 4,491,526 hours (Table 3). The submission notes an overall decrease of 4,225,729 hours and a decrease of 321,202 responses and states there were 8,931 certified mammography facilities as of October 1, 2024.
Patient-Facing Reporting Requirements
The rule requires patient-facing reporting such as a lay summary of the examination and breast density reporting in mammography reports. The document quantifies these burdens: the lay summary activity is estimated at 3,769,373 total annual hours and breast density reporting (one-time burden) is estimated at 205,413 hours.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-04938 — Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
The FDA wants your thoughts on how it collects info about new drug tests before they’re approved. This affects drug companies and researchers who submit applications to test new medicines. You’ve got until May 12, 2026, to share your comments, helping shape smoother, clearer rules without extra costs or delays.
Next: 2026-04940 — Agency Information Collection Activities; Proposed Collection; Comment Request; Animal Food and Egg Regulatory Program Standards
The FDA is updating how it collects info about egg safety rules to keep food safe and healthy. This affects state and local food safety teams who help protect us from foodborne illnesses. They’re asking for your thoughts by April 13, 2026, to make sure the process is smooth and effective—no big cost changes expected!
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in